- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02135861
A Method Validation Study for Evaluation of Novel Treatments Limiting Pulmonary Oedema in Cardiac Failure
An Evaluation of DCE-MRI Measures of Pulmonary Oedema and Vascular Permeability in Healthy Subjects and in Patients With Cardiac Failure: A Methods Validation Study for Evaluation of Novel Treatments Limiting Pulmonary Oedema in Cardiac Failure
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Cambridge, United Kingdom, CB2 2GG
- GSK Investigational Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or females over 18 years of age at the time of signing the informed consent.
- Body weight >=50 kilogram (kg) and Body Mass Index (BMI) within the range 18.0-40.0 kilogram/square meter (kg/m^2) (inclusive).
- Able to understand and comply with protocol requirements, instructions and protocol stated restrictions and is willing to take part in the imaging sessions.
- Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.
Inclusion Criteria for Heart Failure Group (group 2) - Established diagnosis of mild to moderate heart failure of any aetiology with symptoms defined as corresponding to the New York Heart Association (NYHA) class II or III.
Inclusion Criteria for Healthy Volunteer Group (group 1)
- Healthy as determined by a responsible and experienced physician, based on a medical evaluation including medical history, brief physical examination, clinical laboratory tests, and Electrocardiogram (ECG).
Inclusion Criteria for Subjects with ADHF (Group 3)
- Male subjects OR female subjects of non reproductive potential as defined as pre-menopausal females with a documented tubal ligation or hysterectomy, or post-menopausal defined as 12 months of spontaneous amenorrhea [in questionable cases a blood sample with simultaneous follicle stimulating hormone (FSH) > 40 million international units (MIU)/millilitre (mL) and oestradiol < 40picogram (pg)/mL (< 140 pmol/L) is confirmatory.
- 50 years of age or over at the time of signing the informed consent
- Hospitalized for the management of acute decompensated HF
- Presence of dyspnoea at rest or with minimal activity
- Presence of at least one of the following signs: Tachypnea with respiratory rate >=20 breaths/min or Rales or crackles audible on auscultation
- Chest x-ray with evidence of pulmonary congestion/oedema performed approximately within the last 48 hours (if not available - an additional research CXR may be requested)
- Have received at least one treatment with an intravenous diuretic prior to the first MRI scan
- Body weight >= 50kg and BMI within the range 18-40 kg/m^2 (inclusive)
- Able to understand and comply with protocol requirements, instructions and protocol-stated restrictions and is willing to take part in the imaging sessions
- Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form
Exclusion criteria:
Exclusion Criteria for Heart Failure Group
- History of known primary pulmonary disease requiring current medication or other therapy.
- Orthopnoea of sufficient severity to preclude supine scanning as determined at screening.
- Unstable angina within the past 3 months.
- Uncontrolled hypertension (resting systolic Blood Pressure (BP) >160 millimeters of mercury (mmHg) or resting diastolic BP >100 mmHg).
- Resting hypoxia while breathing room air (Saturation of Oxygen [SaO2] <88%). Exclusion Criteria for Healthy Volunteer Group and Heart Failure Groups
- Current smoker, defined as having smoked in the preceding 6 months.
- Contraindication for MRI scanning (as assessed by local MRI safety questionnaire) which includes but not limited to: Intracranial aneurysm clips or other metallic objects; Intra-orbital metal fragments that have not been removed ; Pacemakers or other implanted cardiac rhythm management devices and non-MRI compatible heart valves; Inner ear implants; and History of claustrophobia.
- Pregnant females as determined by positive urine human chorionic gonadotropin (HCG) test at screening or any scanning session.
- Positive test for drugs of abuse, not due to current prescription drugs as determined by the GSK Medical Monitor and principal investigator (PI), and alcohol screen.
- Estimated Creatinine Clearance (Cockcroft-Gault) <60 millilitre (mL)/minute.
Exclusion Criteria for Subjects with ADHF (Group 3)
- End-stage heart failure defined as requiring left ventricular assist devices, intra-aortic balloon pump or any type of mechanical support
- Chronic or intermittent renal support therapy (hemodialysis, ultrafiltration, or peritoneal dialysis)
- Ongoing or planned intravenous diuretic treatment within 1 hour of MRI scan appointment
- History of known primary pulmonary disease requiring current medication or other therapy
- Orthopnoea of sufficient severity to preclude supine scanning (as determined by a 15-minute test of lying supine with or without the use of oxygen)
- Contraindication for MRI scanning (as assessed by local MRI safety questionnaire), which includes but is not limited to: Intracranial aneurysm clips (except Sugita) or other metallic objects OR intra-orbital metal fragments that have not been removed OR pacemakers or other implanted cardiac rhythm management devices and non-MRI compatible heart valves OR inner ear implants OR history of claustrophobia
- Estimated creatinine clearance (Cockcroft-Gault) <40mL/minute
- Contraindication to MRI contrast agents
- Previous inclusion in a research and/or medical protocol involving nuclear medicine, PET or radiological investigations with significant radiation burden(a significant radiation burden being defined as 10 millisieverts (mSv) in addition to natural background radiation, in the previous 3 years including the dose from this study).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Healthy volunteers
All subjects will undergo MRI scanning conducted by experienced radiographers and radiologists in the nominated scanning sites, using a 1.5 Tesla (T) system.
|
Subjects will be placed supine in the scanner and will be prepared for intravenous contrast agent administration.
The contrast agent is administered using a power injector before imaging.
Gadobutrol at a dose less than or equal to 0.1 millimoles per kilogram (mmol/kg) will be given intravenously as a bolus using a power injector.
|
Experimental: Heart failure patients
All subjects will undergo DCE-MRI scanning conducted by experienced radiographers and radiologists in the nominated scanning sites, using a 1.5 T system.
|
Subjects will be placed supine in the scanner and will be prepared for intravenous contrast agent administration.
The contrast agent is administered using a power injector before imaging.
Gadobutrol at a dose less than or equal to 0.1 millimoles per kilogram (mmol/kg) will be given intravenously as a bolus using a power injector.
|
Experimental: Acute decompensated heart failure
All subjects will undergo DCE-MRI scanning conducted by experienced radiographers and radiologists in the nominated scanning sites, using a 1.5 T system
|
Subjects will be placed supine in the scanner and will be prepared for intravenous contrast agent administration.
The contrast agent is administered using a power injector before imaging.
Gadobutrol at a dose less than or equal to 0.1 millimoles per kilogram (mmol/kg) will be given intravenously as a bolus using a power injector.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Interstitial Volume (ve) in Heart Failure Participants and Healthy Volunteers at Baseline
Time Frame: Day 1
|
Interstitial volume (ve) was measured by DCE-MRI.
ve for total lung, left lung, right lung, left lung apical, left lung basal, right lung apical, right lung basal has been presented.
Session 1 values were considered as Baseline values.
|
Day 1
|
Exchange Rate (Ktrans) in Heart Failure Participants and Healthy Volunteers at Baseline
Time Frame: Day 1
|
Exchange rate (Ktrans) was measured by DCE-MRI.
Ktrans for total lung, left lung, right lung, left lung apical, left lung basal, right lung apical, right lung basal has been presented.
Session 1 values were considered as Baseline values.
|
Day 1
|
Interstitial Volume (ve) in Heart Failure Participants and Healthy Volunteers Before and Following Exercise
Time Frame: Day 11
|
Interstitial volume (ve) was measured by DCE-MRI.
ve for total lung, left lung, right lung, left lung apical, left lung basal, right lung apical, right lung basal before and following exercise has been presented.
|
Day 11
|
Exchange Rate (Ktrans) in Heart Failure Participants and Healthy Volunteers Before and Following Exercise
Time Frame: Day 11
|
Exchange rate (Ktrans) was measured by DCE-MRI.
Ktrans for total lung, left lung, right lung, left lung apical, left lung basal, right lung apical, right lung basal before and following exercise has been presented.
|
Day 11
|
Change in Interstitial Volume (ve) in ADHF Participants
Time Frame: Up to Week 8
|
Interstitial volume (ve) was measured by DCE-MRI.
Three participants underwent 3 DCE-MRI scans.
The data has been presented for individual participant in each session.
The data presented below is only for total lung.
|
Up to Week 8
|
Change in Exchange Rate (Ktrans) in ADHF Participants
Time Frame: Up to Week 8
|
Exchange rate (Ktrans) was measured by DCE-MRI.
Three participants underwent 3 DCE-MRI scans.
The data has been presented for individual participant in each session.
The data presented below is only for total lung.
|
Up to Week 8
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Assessment of Intra-subject Variability in Ve Between Session 1 and Session 2 of DCE-MRI
Time Frame: Day 1 (Session 1) and Day 9 (Session 2)
|
Coefficient of variation (percentage) of intra-subject variability in Ve between Session 1 and Session 2 for total lung has been presented.
|
Day 1 (Session 1) and Day 9 (Session 2)
|
Assessment of Intra-subject Variability in Ktrans Between Session 1 and Session 2 of DCE-MRI
Time Frame: Day 1 (Session 1) and Day 9 (Session 2)
|
Coefficient of variation (percentage) of intra-subject variability in Ktrans between Session 1 and Session 2 for total lung has been presented.
|
Day 1 (Session 1) and Day 9 (Session 2)
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 201137
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Heart Failure, Congestive
-
Echosense Ltd.WithdrawnCongestive Heart Failure (CHF)United States
-
Corthera, Inc.(formerly BAS Medical, Inc.), a member...TerminatedCongestive Heart Failure (CHF)Russian Federation
-
Meir Medical CenterUnknown
-
Nihon KohdenTerminatedHeart Failure,CongestiveUnited States
-
Adnan Kastrati, MDBiotronik SE & Co. KGCompleted
-
Signature Medical, Inc.WithdrawnHeart Failure,Congestive
-
Abbott Medical DevicesCompletedCongestive Heart Failure TreatedItaly
-
Echosense Ltd.Terminated
-
ELA Medical, Inc.Approved for marketing
-
Magenta Medical Ltd.TerminatedCongestive Heart Failure | Heart Failure, Congestive | Acute Heart FailureCroatia, Belgium, Serbia
Clinical Trials on DCE-MRI scans
-
Memorial Sloan Kettering Cancer CenterCompletedOvarian CancerUnited States
-
American College of Radiology Imaging NetworkNational Cancer Institute (NCI); Eastern Cooperative Oncology GroupUnknownBreast Cancer | BIRADS 3 | BIRADS 4 | BIRADS 5United States
-
Stanford UniversityColumbia University; University of ManchesterRecruiting
-
Yonsei UniversityUnknownAdvanced Adult Hepatocellular CarcinomaKorea, Republic of
-
The First Hospital of Hebei Medical UniversityUnknown
-
University of UtahCompleted
-
Memorial Sloan Kettering Cancer CenterUniversity of Oregon; University College, London; New York Presbyterian Hospital and other collaboratorsCompleted
-
University of Wisconsin, MadisonNational Institute of Neurological Disorders and Stroke (NINDS); National Institutes...CompletedBrain InjuriesUnited States, United Kingdom, Australia
-
London Health Sciences CentreCompleted
-
OHSU Knight Cancer InstituteRadiological Society of North America; Medical Research Foundation, OregonTerminatedHead and Neck CancerUnited States